newsfilter
← Latest News
GlobeNewswire·

Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA

  • FDA agreed to Annovis Bio's plan to pool safety data from Alzheimer's & Parkinson's studies & integrate it at the standardized analysis dataset level.
  • The Integrated Summary of Safety (ISS) package will be built in parallel with ongoing trials ahead of the planned New Drug Application (NDA) submission.
  • NDA submission is scheduled to occur following the data readout from the active Phase 3 DUET-AD study.
  • The pooled analysis combines data from three randomized, double-blind, placebo-controlled studies & one open-label extension study.
  • Included studies are the completed Phase 3 PD trial (NCT05357989), completed Phase 2/3 AD trial (NCT05686044), active DUET-AD trial (NCT06709014), & active OLE PD trial (NCT07284784).
  • Annovis anticipates over 1,600 participants will have received buntanetap across these pooled studies by the 6-month DUET-AD readout.
  • FDA provided recommendations on statistical methods for the integrated analysis which Annovis will incorporate into its final ISS statistical plan.
  • The pooling strategy relies on buntanetap's common mechanism of action, comparable pharmacokinetics, & similar safety profiles across both disease programs.
  • FDA's agreement on the pooling strategy does not constitute drug approval or guarantee NDA acceptance.
  • Annovis Bio is a Phase 3 clinical-stage company developing buntanetap, an investigational once-daily oral therapy targeting neurodegenerative proteins.
Company
Annovis Bio Inc.
Keywords
NYSE:ANVS, Annovis Bio Inc.